Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 3 Interventional

Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

ClinicalTrials.gov ID: NCT01456013

Public ClinicalTrials.gov record NCT01456013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Contrast-Induced Nephropathy (CIN) can occur when patients with pre-existing kidney problems undergo procedures that use iodinated contrast media, such as cardiac catheterizations. RenalGuard Therapy was developed to enable the patient to clear the contrast out of their kidney before it can do significant damage. This study aims to enroll patients with increased risk of developing CIN who are scheduled for a cardiovascular catheterization. Patients will be randomized to either RenalGuard therapy or standard therapy.

Study identification

NCT ID
NCT01456013
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 3
Lead sponsor
CardioRenal Systems, Inc.
Industry
Enrollment
326 participants

Conditions and interventions

Interventions

Device · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2011
Primary completion
Feb 28, 2018
Completion
Nov 30, 2024
Last update posted
Feb 15, 2023

2012 – 2024

United States locations

U.S. sites
30
U.S. states
17
U.S. cities
26
Facility City State ZIP Site status
University of Alabama Birmingham Alabama 35924
Torrance Medical Center Torrance California 90505
Washington Hospital Center Washington D.C. District of Columbia 20010
Clearwater Cardiovascular Clearwater Florida 33756
University of Florida Jacksonville Florida 32209
Northwestern Memorial Hospital Chicago Illinois 60611
Advocate Good Samaritan Downers Grove Illinois 60515
Advocate Health Naperville Illinois 65040
Johns Hopkins University Baltimore Maryland 21218
St. Elizabeth's Hospital Brighton Massachusetts 02135
Cape Cod Healthcare Hyannis Massachusetts 02601
University of Massachusetts Worcester Massachusetts 01655
Northern Michigan Hospital Petoskey Michigan 49770
Abbott Northwestern Minneapolis Minnesota 55407
North Mississippi Medical Center Tupelo Mississippi 38801
St. Joseph Medical Center Saint Charles Missouri 63301
NYU Medical Center New York New York 10016
Mount Sinai Medical Center New York New York 10029
Columbia University New York New York 10032
Montefiore Medical Center New York New York 10467
Stony Brook University Medical Center Stony Brook New York 11794
Rex Hospital Raleigh North Carolina 27607
St. John Research Institute Bartlesville Oklahoma 74006
University of Pittsburgh Pittsburgh Pennsylvania 15213
Guthrie Medical Center Sayre Pennsylvania 18840
Rhode Island Hospital Providence Rhode Island 02903
The Miriam Hospital Providence Rhode Island 02906
Austin Heart Central Austin Texas 78756
Baylor Scott & White Plano Texas 75093
Austin Heart Round Rock Round Rock Texas 78681

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01456013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 15, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01456013 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →